Preview: academician Chen Kaixian, research and development branch of innovative drugs

Chen Kaixian, academician of the third branch of innovative drug research and development of 2015 international bioeconomy conference, made a keynote report on drug innovation and development strategy of the 13th five year plan, The author of yaozhi.com learned at the third branch of international bioeconomy conference innovative drug research and Development held in the lecture hall on the third floor of conference center of Tianjin International Biomedical joint research institute that academician Chen Kaixian, research leader of Shanghai Institute of medicine and doctoral supervisor of Chinese Academy of Sciences, said in the theme report of Research on drug innovation and "13th five year" development strategy, Big data, biosimilars, clinical histology, Ebola and other emerging viruses, epigenetics, immunooncology, M & A activities, nanodrugs, personalized medicine, synthetic biology will be the major trend of biomedicine in the future Academician Chen Kaixian pointed out that in recent years, the risk of drug development in China has increased In recent two years, the clinical research of new drugs has encountered major setbacks, and in the past 10 years, the research and development of ad drugs has encountered comprehensive failures From 2002 to 2012, the clinical research and analysis of Alzheimer's drugs found that up to 99.6% of clinical trials ended in failure The input-output ratio of R & D is continuously decreasing For the judgment of biomedical trends in 2015, academician Chen Kaixian believes that big data, bio generic drugs, clinical histology, Ebola and other emerging viruses, epigenetics, immunooncology, M & A activities, nanodrugs, personalized medicine and synthetic biology will be the top ten biomedical trends At the same time, M & A activities will continue to constitute a trend of financial and resource allocation The development space of Chinese medicine market is huge, and the scale of medicine market has ranked the second in the world The development of China's pharmaceutical industry is in good shape The industrial scale continues to grow rapidly, the technological innovation achievements are remarkable, the strength of enterprises is significantly enhanced, and the level of internationalization is improved But the problems are also very prominent Academician Chen Kaixian pointed out that: China's scientific and technological innovation and achievement transformation capacity are weak, drug research and development is still dominated by follow-up and imitation, and the original innovation is insufficient; the product structure needs to be upgraded; the industrial concentration is low, the low-level duplication is prominent, and the enterprises with international influence are lack; the level of drug quality and safety assurance needs to be improved; international pharmaceutical giants are stepping up to seize the domestic market; production, learning and research The mechanism and environment for innovation need to be further built due to the virtual alliance; the policies and regulations are not sound enough, and the management ability needs to be strengthened The current situation of "big but not strong" industry has not been fundamentally changed In terms of strategies and methods for drug innovation, academician Chen Kaixian believes that: we need to develop innovative strategies for comprehensive promotion; transformation of medicine and new drug research mode; new drug research based on System Biomedicine and clinical needs; biomarker and new drug research; modeling and modeling methods and strategies; new drug research based on natural products and traditional Chinese medicine; and aim at the international forefront To strengthen the original innovation; to highlight the demand orientation and solve major problems, such as the research of drug-resistant bacteria Academician Chen Kaixian talked about the expected objectives and assessment indicators of the 13th five year plan: innovative drug research and development of 30 new drugs, 8-10 of which are original new drugs; development and promotion of 20-30 chemical drugs and high-end preparations, 3-5 new Chinese medicines, 3-5 new biological drugs internationalization; development of 20-30 clinically important varieties; breakthrough of 10-15 major core key technologies, and development of 10-15 prospective To establish a national drug innovation system with Chinese characteristics and a new model of collaborative innovation, so as to make the overall level reach the international advanced level Finally, academician Chen Kaixian sent a message to the guests: "at present, the 13th five year plan is about to start China's innovative drug research and the development of pharmaceutical industry are facing rare historical opportunities, and are at a historical turning point from a large country to a powerful country We should seize the opportunities, meet the challenges and achieve new development goals "